Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

The Society for Obstetrics and Gynecology of Canada has issued updated guidelines for the management of uterine fibroids (uterine leiomyomas), which now include the first and only approved medical treatment for uterine fibroids: FIBRISTAL (ulipristal acetate).

4 Jun 2015

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System are the first in the United States to treat osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method.

28 May 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

The Ontario Health Technology Advisory Committee has recommended Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU or MRgFUS) as a possible "cost-effective strategy" and a "safe and effective, noninvasive, uterine-preserving" option for women seeking treatment for uterine fibroids.

27 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

The relative cost, benefits, and complications of three minimally invasive techniques for reducing or eliminating symptomatic uterine fibroids are being compared in women who don't have cancer and want to preserve their uterus.

30 Mar 2015

VIVA physician selected as new Fellows in the Society of Interventional Radiology

Dr. John D. Statler, a board-certified, fellowship-trained Interventional Radiologist with Virginia Interventional & Vascular Associates, is one of only 23 physicians nationwide selected this year as new Fellows in the Society of Interventional Radiology.

26 Mar 2015

Laparoscopic hysterectomy with morcellation safer than abdominal procedure for treating presumed fibroid uterus

In a new study published in the American Journal of Obstetrics & Gynecology, researchers from The University of North Carolina at Chapel Hill compared the relative risks of laparoscopic hysterectomy (with morcellation) with abdominal surgery for hysterectomy in premenopausal women undergoing surgery for presumed uterine fibroids.

25 Mar 2015

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2014 and provided a corporate update.

13 Mar 2015

Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Uterine sarcoma - a potentially aggressive type of cancer that forms in tissues in the uterus - was found in 0.22 % of women following a hysterectomy for benign conditions, a new large-scale study by the University of Michigan departments of Obstetrics and Gynecology, and Surgery finds.

20 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Study finds unnecessary hysterectomy in 1 out of 5 cases

It is estimated that one in three women in the United States will have had a hysterectomy by the age of 60. Although the numbers of hysterectomies are decreasing, a new study of more than three thousand women in Michigan who underwent hysterectomy for benign indications reveals that alternatives to hysterectomy are being underused and that treatment guidelines are often not followed.

7 Jan 2015

Report supports potential of focused ultrasound to treat certain OCD patients

A recently published report in the Journal of Molecular Psychiatry supports the potential of focused ultrasound to treat certain patients with obsessive-compulsive disorder (OCD).

10 Dec 2014

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

The U.S. Food and Drug Administration is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids, which is in keeping with Kalorama Information's view that in the female health market there is much room for improvement both in the development of products and the treatment of diseases.

29 Nov 2014

InSightec's MRgFUS system approved in Japan for treatment of women with uterine fibroids

Elbit Imaging Ltd. announced today that it was informed by InSightec Ltd. that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved InSightec's MR-guided Focused Ultrasound (MRgFUS) system for the treatment of pain palliation caused by bone metastases and advanced treatment for women with uterine fibroids.

25 Nov 2014

Promising molecular diagnostic approach to endometriosis

Researchers at UC San Francisco have identified patterns of genetic activity that can be used to diagnose endometriosis and its severity, a finding that may offer millions of women an alternative to surgery through a simple noninvasive procedure.

21 Nov 2014

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

Researchers at the University of Texas Medical Branch at Galveston, in collaboration with The University of Texas Health Science Center at Houston (UTHealth), Baylor College of Medicine and the Georgia Regents University, report for the first time that the cholesterol-lowering drug simvastatin inhibits the growth of human uterine fibroid tumors.

16 Nov 2014

New book offers advice on how to meet contraceptive needs of women with chronic medical problems

Women with chronic medical conditions can be at higher risk for complications during pregnancy and therefore require specialized preconception and contraceptive care and counseling. However, many medical providers are hesitant to prescribe contraception to these women due to concerns about the safety of various contraceptives with co-existing medical disorders.

16 Oct 2014

InSightec to share new insights at FUS symposium

InSightec, world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the Focused Ultrasound International Symposium (FUS) to share key insights gained in the past two years of using its non-invasive MRgFUS solution for treating a variety of neurosurgical, oncological and gynecological indications.

9 Oct 2014

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update.

12 Aug 2014

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Neurocrine reports net loss of $1.2 million for first quarter 2015

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

Alternative treatment options for uterine fibroids

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

VIVA physician selected as new Fellows in the Society of Interventional Radiology

Laparoscopic hysterectomy with morcellation safer than abdominal procedure for treating presumed fibroid uterus

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Actavis provides overview of standalone global pharmaceutical development pipeline

Study finds unnecessary hysterectomy in 1 out of 5 cases

Report supports potential of focused ultrasound to treat certain OCD patients

FDA takes immediate steps to help reduce risk of spreading unsuspected uterine cancer

InSightec's MRgFUS system approved in Japan for treatment of women with uterine fibroids

Promising molecular diagnostic approach to endometriosis

Cholesterol-fighting statins inhibit uterine fibroid tumors that account for 50% of hysterectomies

New book offers advice on how to meet contraceptive needs of women with chronic medical problems

InSightec to share new insights at FUS symposium

BioSpecifics Technologies total revenue for second quarter decreases by 19%

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in